What happened
- The FDA approved Sunharbo (asundexian 50 mg, Bayer) on 9 Nov 2026, taken with antiplatelet therapy after a recent mild-to-moderate non-cardioembolic stroke or a high-risk mini-stroke (TIA).
- In the phase 3 OCEANIC-STROKE trial of 12,327 adults, it reduced the risk of ischemic stroke by 26% versus placebo over a median of 14.2 months.
- Major bleeding overall was similar to placebo.
What we don't know yet
- Bleeding was higher in people over 75 and in the first 90 days. Gastrointestinal bleeding was more common.
- It is not approved for stroke prevention in atrial fibrillation.
Primary sources
- FDA press announcement, 9 Nov 2026Regulator decision
Not medical advice. This is a summary of published results, not a recommendation. Ask your own doctor whether any treatment or trial fits you. To look for trials near you, search ClinicalTrials.gov or the WHO trial registry portal.